
News|Videos|June 4, 2015
Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
Author(s)Dung T. Le, MD
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Advertisement
In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
Weighing Bispecific Antibodies Against CAR T-Cell Therapy in Follicular Lymphoma
3
Talazoparib/Enzalutamide sNDA Receives FDA Priority Review in HRR+ CSPC
4
Teclistamab Combos Improve PFS, OS in Relapsed/Refractory Multiple Myeloma
5




















































